Liquid Formulation of Lisdexamfetamine Expands Options for Patients With ADHD

Gregory Busse, PhD, director and medical lead for CNS in medical affairs at Azurity Pharmaceuticals, shared more about Arynta—a ready-to-use oral solution of lisdexamfetamine—and outlined the clinical rationale for its use in attention-deficit hyperactive disorder (ADHD). Busse identified Arynta's approved indications as ADHD in adults and children aged 6 years and older, as well as moderate to severe binge eating disorder.¹

He noted that while other stimulant oral solutions exist on the market, Arynta is the only approved oral solution of lisdexamfetamine specifically. As a prodrug stimulant, lisdexamfetamine carries a schedule II classification shared by all stimulants approved for ADHD. Busse argued that individualized stimulant selection requires attention to both pharmacological and patient-level variables, stating that "not all stimulants are created equal" in terms of pharmacokinetic profiles and receptor binding, and that "not all ADHD patients are created equal either," given differences in treatment preferences, comorbidities, age, and adverse event tolerability.²

He framed the oral solution formulation as particularly valuable for patients who have difficulty swallowing pills or who prefer a liquid dosage form due to other disorders. Busse then addressed the challenge of medication aversiveness in pediatric ADHD, describing pill refusal as "the eating the vegetables phenomenon"—a learned behavior that liquid formulations could help circumvent while maintaining effective treatment.

He further identified comorbid sensory difficulties, conduct problems, mood disturbances, and anxiety as conditions that compound barriers to adherence, emphasizing that an oral liquid formulation could reduce those barriers meaningfully.

Dr Busse is the director, medical lead of CNS at Azurity Pharmaceuticals.

References

1. Arynta label. US Food and Drug Administration. Accessed May 6, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219847s000lbl.pdf

2. Thirstrup JP, Duan J, Haro MR, et al. Common and rare variant contributions to discontinuation of stimulant treatment in ADHD. Transl Psych. 2026;16:144.